AU7874591A - Hybrid plasminogen activator mutants - Google Patents

Hybrid plasminogen activator mutants

Info

Publication number
AU7874591A
AU7874591A AU78745/91A AU7874591A AU7874591A AU 7874591 A AU7874591 A AU 7874591A AU 78745/91 A AU78745/91 A AU 78745/91A AU 7874591 A AU7874591 A AU 7874591A AU 7874591 A AU7874591 A AU 7874591A
Authority
AU
Australia
Prior art keywords
plasminogen activator
hybrid plasminogen
mutants
activator mutants
hybrid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU78745/91A
Inventor
Ian Dodd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beecham Group PLC
Original Assignee
Beecham Group PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beecham Group PLC filed Critical Beecham Group PLC
Publication of AU7874591A publication Critical patent/AU7874591A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
AU78745/91A 1990-05-26 1991-05-21 Hybrid plasminogen activator mutants Abandoned AU7874591A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9011861A GB9011861D0 (en) 1990-05-26 1990-05-26 Novel compounds
GB9011861 1990-05-26

Publications (1)

Publication Number Publication Date
AU7874591A true AU7874591A (en) 1991-12-31

Family

ID=10676651

Family Applications (1)

Application Number Title Priority Date Filing Date
AU78745/91A Abandoned AU7874591A (en) 1990-05-26 1991-05-21 Hybrid plasminogen activator mutants

Country Status (3)

Country Link
AU (1) AU7874591A (en)
GB (1) GB9011861D0 (en)
WO (1) WO1991018989A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US6465424B1 (en) * 1999-02-17 2002-10-15 Bristol-Myers Squibb Company Anti-angiogenic agent and method for inhibiting angiogenesis
US7094579B2 (en) 2002-02-13 2006-08-22 Xoma Technology Ltd. Eukaryotic signal sequences for prokaryotic expression
EP1947116B1 (en) 2003-02-10 2017-06-21 2-BBB Medicines B.V. Differentially expressed nucleic acids in the blood-brain barrier under inflammatory conditions
WO2010087702A1 (en) 2009-01-30 2010-08-05 Stichting Katholieke Universiteit TET2 gene as a marker for diagnosing a myelodysuplastic syndrome (MDS) or an acute myeloid leukemia (AML) and determining the prognosis in a subject
EP2478101A1 (en) 2009-09-16 2012-07-25 Stichting Het Nederlands Kanker Instituut Fra-1 target genes as drug targets for treating cancer
EP2305717A1 (en) 2009-09-21 2011-04-06 Koninklijke Nederlandse Akademie van Wetenschappen Inhibiting TNIK for treating colon cancer
WO2011036555A1 (en) 2009-09-25 2011-03-31 University Of Oslo Multivalent phage display systems and methods
EP2354245A1 (en) 2010-02-04 2011-08-10 Stichting Top Institute Food and Nutrition MBL2 as a marker of hepatic PPAR- activity
EP2354244A1 (en) 2010-02-04 2011-08-10 Stichting Top Institute Food and Nutrition MBL2 as a marker of liver-specific insulin resistance
US9499813B2 (en) 2010-06-10 2016-11-22 President And Fellows Of Harvard College Systems and methods for amplification and phage display
US9551717B2 (en) 2010-08-17 2017-01-24 Stichting Katholieke Universiteit Method for diagnosing Q-fever using a cellular immunological test
RU2013118307A (en) 2010-09-21 2014-10-27 Стихтинг Катхолике Юниверситейт A NEW METHOD FOR DIAGNOSTIC OF LYME DISEASE USING A CELL IMMUNE RESPONSE TEST
EP2465928A1 (en) 2010-12-16 2012-06-20 Academisch Medisch Centrum bij de Universiteit van Amsterdam Treatment of Th17-mediated diseases
WO2014142646A1 (en) 2013-03-13 2014-09-18 Stichting Katholieke Universiteit Q-fever diagnostic
WO2014178715A1 (en) 2013-05-02 2014-11-06 Stichting Katholieke Universiteit Personalised medicine
EP3283512A4 (en) 2015-04-17 2018-10-03 Distributed Bio Inc Method for mass humanization of non-human antibodies
EP3288973B1 (en) 2015-04-30 2021-10-20 AbCheck s.r.o. Method for mass humanization of rabbit antibodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ191320A (en) * 1978-09-07 1982-09-14 Beecham Group Ltd In vivo fibrinolytic enzyme having active site blocked by hydrolytically removable group pharmaceutical compositions
DE3883453T2 (en) * 1987-07-01 1994-03-17 Beecham Group Plc Hybrid plasminogen activators.
DE69033699T2 (en) * 1989-03-06 2001-05-23 The Board Of Regents Of The University Of Texas System, Austin T-PA MUTANTS RESISTANT TO OWN INHIBITORS

Also Published As

Publication number Publication date
WO1991018989A1 (en) 1991-12-12
GB9011861D0 (en) 1990-07-18

Similar Documents

Publication Publication Date Title
AU4894893A (en) Refrigerator
AU7937791A (en) Culture bag
AU4166393A (en) Auto-reclosers
AU3561193A (en) TNF-muteins
AU7874591A (en) Hybrid plasminogen activator mutants
AU3991693A (en) Pyrazinoindoles
AU3042892A (en) Rockbolt
AU4177593A (en) Benzophenonehydrazones
AU8239291A (en) Two compartment syringe
AU667580B2 (en) Line-handling block
AU4156393A (en) Heterocyclyltriazolinones
AU664253B2 (en) Photo-deviometer
AU3461693A (en) Saddle-cloth
AU3562193A (en) Morpholin- and thiomorpholin-4-ylamides
AU4164793A (en) Heterocyclyltriazolinones
AU8442291A (en) Hybrid plasminogen activators
AU4632493A (en) Weathershed
AU3200493A (en) Ganglioside-GM3-fortified nutrient composition
AU6159594A (en) Ashtray
AU4864693A (en) Alkoxymethyl-substituted pyridonebiphenyls
AU3185693A (en) Pyrrolylbenzodiazepinones
AU3895593A (en) Biocatalysis
AU4305393A (en) Arrangement with blocks
AU3506993A (en) Furniture
AU5564794A (en) Play-mark